HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Breast cancer risk for women with diabetes and the impact of metformin: A meta-analysis.

AbstractBACKGROUND:
Diabetes mellitus has been associated with increased breast cancer (BC) risk; however, the magnitude of this effect is uncertain. This study focused on BC risk for women with type 2 diabetes mellitus (T2DM).
METHODS:
Two separate meta-analyses were conducted (1) to estimate the relative risk (RR) of BC for women with T2DM and (2) to evaluate the risk of BC for women with T2DM associated with the use of metformin, a common diabetes treatment. In addition, subgroup analyses adjusting for obesity as measured by body mass index (BMI) and menopausal status were also performed. Studies were identified via PubMed/Scopus database and manual search through April 2021.
RESULTS:
A total of 30 and 15 studies were included in the first and second meta-analyses, respectively. The summary RR of BC for women with T2DM was 1.15 (95% confidence interval [CI], 1.09-1.21). The subgroup analyses adjusting BMI and adjusting BMI and menopause resulted in a summary RR of 1.22 (95% CI, 1.15-1.30) and 1.20 (95% CI, 1.05-1.36), respectively. For women with T2DM, the summary RR of BC was 0.82 (95% CI, 0.60-1.12) for metformin users compared with nonmetformin users.
CONCLUSIONS:
Women with T2DM were more likely to be diagnosed with BC and this association was strengthened by adjusting for BMI and menopausal status. No statistically significant reduction of BC risk was observed among metformin users.
IMPACT:
These two meta-analyses can inform decision-making for women with type 2 diabetes regarding their use of metformin and the use of screening mammography for early detection of breast cancer.
AuthorsYifan Lu, Ali Hajjar, Vincent L Cryns, Amy Trentham-Dietz, Ronald E Gangnon, Brandy M Heckman-Stoddard, Oguzhan Alagoz
JournalCancer medicine (Cancer Med) Vol. 12 Issue 10 Pg. 11703-11718 (05 2023) ISSN: 2045-7634 [Electronic] United States
PMID36533539 (Publication Type: Meta-Analysis, Journal Article, Review, Research Support, N.I.H., Extramural)
Copyright© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Chemical References
  • Metformin
  • Hypoglycemic Agents
Topics
  • Female
  • Humans
  • Metformin (adverse effects)
  • Diabetes Mellitus, Type 2 (complications, drug therapy, epidemiology)
  • Hypoglycemic Agents (adverse effects)
  • Breast Neoplasms (epidemiology)
  • Risk
  • Mammography
  • Early Detection of Cancer

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: